

FGF23 at the Intersection of Kidney and Cardiovascular Disease

ABOUT THE LECTURE

Elevation of fibroblast growth factor 23 (FGF23) levels is an early and pervasive complication of chronic kidney disease (CKD) that triggers the pathogenesis of secondary hyperparathyroidism. Elevated FGF23 is also a potent biomarker and perhaps, novel molecular mechanism of heart failure and death in patients CKD. This presentation include aims to help audience members:

1. Understand the role of FGF23 in normal mineral metabolism and in CKD
2. Understand the off-target cardiovascular effects of FGF23
3. Understand mechanisms of FGF23 regulation

Speaker: **Prof Myles Wolf**

**Charles Johnson, MD Distinguished Professor of Medicine
Chief, Duke Nephrology
Duke University School of Medicine**



Host: **Prof Thomas Coffman**

**Dean
Duke-NUS Medical School**

Date: **Thursday, 7 July 2022**

Time: **12.00 PM - 1.00 PM**

Venue: **For in-person attendance (by registration only), please register [HERE](#).**
(Limited seats available in the Amphitheatre. Registration will be on a first-come-first-served basis)

For virtual seminar (via Zoom), please register [HERE](#).
(Please rename your login name to include your institution to facilitate admission)

Contact **Ms Kathleen Chan (kathleen.chan@duke-nus.edu.sg)**

Person: **Duke-NUS Research Affairs Department**

ABOUT THE SPEAKER

Myles Wolf received his MD from the State University of New York–Downstate, completed Internal Medicine and Nephrology training at the Massachusetts General Hospital, and obtained a Master of Medical Sciences degree in Clinical and Physiological Investigation from Harvard Medical School. The focus of Dr. Wolf's clinical and basic research is disordered mineral metabolism across the spectrum of kidney disease from early stages to end-stage renal disease and following kidney transplantation.

** Please be informed that photography and videography may be taken by Duke-NUS authorized personnel during the event for publicity purposes.*